Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Prateek Singh; Rajat Ujjainiya; Satyartha Prakash; Salwa Naushin; Viren Sardana; Nitin Bhatheja; Ajay Pratap Singh; Joydeb Barman; Kartik Kumar; Raju Khan; Karthik Bharadwaj Tallapaka; Mahesh Anumalla; Amit Lahiri; Susanta Kar; Vivek Bhosale; Mrigank Srivastava; Madhav Nilakanth Mugale; C.P Pandey; Shaziya Khan; Shivani Katiyar; Desh Raj; Sharmeen Ishteyaque; Sonu Khanka; Ankita Rani; Promila; Jyotsna Sharma; Anuradha Seth; Mukul Dutta; Nishant Saurabh; Murugan Veerapandian; Ganesh Venkatachalam; Deepak Bansal; Dinesh Gupta; Prakash M Halami; Muthukumar Serva Peddha; Gopinath M Sundaram; Ravindra P Veeranna; Anirban Pal; Ranvijay Kumar Singh; Suresh Kumar Anandasadagopan; Parimala Karuppanan; Syed Nasar Rahman; Gopika Selvakumar; Subramanian Venkatesan; MalayKumar Karmakar; Harish Kumar Sardana; Animika Kothari; DevendraSingh Parihar; Anupma Thakur; Anas Saifi; Naman Gupta; Yogita Singh; Ritu Reddu; Rizul Gautam; Anuj Mishra; Avinash Mishra; Iranna Gogeri; Geethavani Rayasam; Yogendra Padwad; Vikram Patial; Vipin Hallan; Damanpreet Singh; Narendra Tirpude; Partha Chakrabarti; Sujay Krishna Maity; Dipyaman Ganguly; Ramakrishna Sistla; Narender Kumar Balthu; Kiran Kumar A; Siva Ranjith; Vijay B Kumar; Piyush Singh Jamwal; Anshu Wali; Sajad Ahmed; Rekha Chouhan; Sumit G Gandhi; Nancy Sharma; Garima Rai; Faisal Irshad; Vijay Lakshmi Jamwal; MasroorAhmad Paddar; Sameer Ullah Khan; Fayaz Malik; Debashish Ghosh; Ghanshyam Thakkar; Saroj K Barik; Prabhanshu Tripathi; Yatendra Kumar Satija; Sneha Mohanty; Md. Tauseef Khan; Umakanta Subudhi; Pradip Sen; Rashmi Kumar; Anshu Bhardwaj; Pawan Gupta; Deepak Sharma; Amit Tuli; Saumya Ray Chaudhuri; Srinivasan Krishnamurthi; Prakash L; Ch V Rao; B N Singh; Arvindkumar Chaurasiya; Meera Chaurasiyar; Mayuri Bhadange; Bhagyashree Likhitkar; Sharada Mohite; Yogita Patil; Mahesh Kulkarni; Rakesh Joshi; Vaibhav Pandya; Amita Patil; Rachel Samson; Tejas Vare; Mahesh Dharne; Ashok Giri; Shilpa Paranjape; G. Narahari Sastry; Jatin Kalita; Tridip Phukan; Prasenjit Manna; Wahengbam Romi; Pankaj Bharali; Dibyajyoti Ozah; Ravi Kumar Sahu; Prachurjya Dutta; Moirangthem Goutam Singh; Gayatri Gogoi; Yasmin Begam Tapadar; Elapavalooru VSSK Babu; Rajeev K Sukumaran; Aishwarya R Nair; Anoop Puthiyamadam; PrajeeshKooloth Valappil; Adrash Velayudhan Pillai Prasannakumari; Kalpana Chodankar; Samir Damare; Ved Varun Agrawal; Kumardeep Chaudhary; Anurag Agrawal; Shantanu Sengupta; Debasis Dash.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21267889

RESUMO

Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the effectiveness of interventions. Asymptomatic breakthrough infections have been a major problem during the ongoing surge of Delta variant globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines used in the higher-income regions. Here, we show for the first time how statistical and machine learning (ML) approaches can discriminate SARS-CoV-2 infection from immune response to an inactivated whole virion vaccine (BBV152, Covaxin, India), thereby permitting real-world vaccine effectiveness assessments from cohort-based serosurveys in Asia and Africa where such vaccines are commonly used. Briefly, we accessed serial data on Anti-S and Anti-NC antibody concentration values, along with age, sex, number of doses, and number of days since the last vaccine dose for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine (SVM) model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, 724 were classified as infected. Since the vaccine contains wild-type virus and the antibodies induced will neutralize wild type much better than Delta variant, we determined the relative ability of a random subset of such samples to neutralize Delta versus wild type strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, Delta variant, was neutralized more effectively than the wild type, which cannot happen without infection. The fraction rose to 71.8% (28 of 39) in subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period.

2.
Salwa Naushin; Viren Sardana; Rajat Ujjainiya; Nitin Bhatheja; Rintu Kutum; Akash Kumar Bhaskar; Shalini Pradhan; Satyartha Prakash; Raju Khan; Birendra Singh Rawat; Giriraj Ratan Chandak; Karthik Bharadwaj Tallapaka; Mahesh Anumalla; Amit Lahiri; Susanta Kar; Shrikant Ramesh Mulay; Madhav Nilakanth Mugale; Mrigank Srivastava; Shaziya Khan; Anjali Srivastava; Bhawna Tomar; Murugan Veerapandian; Ganesh Venkatachalam; Selvamani Raja Vijayakumar; Ajay Agarwal; Dinesh Gupta; Prakash M Halami; Muthukumar Serva Peddha; Gopinath M; Ravindra P Veeranna; Anirban Pal; Vinay Kumar Agarwal; Anil Ku Maurya; Ranvijay Kumar Singh; Ashok Kumar Raman; Suresh Kumar Anandasadagopan; Parimala Karupannan; Subramanian Venkatesan; Harish Kumar Sardana; Anamika Kothari; Rishabh Jain; Anupma Thakur; Devendra Singh Parihar; Anas Saifi; Jasleen Kaur; Virendra Kumar; Avinash Mishra; Iranna Gogeri; Geetha Vani Rayasam; Praveen Singh; Rahul Chakraborty; Gaura Chaturvedi; Pinreddy Karunakar; Rohit Yadav; Sunanda Singhmar; Dayanidhi Singh; Sharmistha Sarkar; Purbasha Bhattacharya; Sundaram Acharya; Vandana Singh; Shweta Verma; Drishti Soni; Surabhi Seth; Firdaus Fatima; Shakshi Vashisht; Sarita Thakran; Akash Pratap Singh; Akanksha Sharma; Babita Sharma; Manikandan Subramanian; Yogendra Padwad; Vipin Hallan; Vikram Patial; Damanpreet Singh; Narendra Vijay Tirpude; Partha Chakrabarti; Sujay Krishna Maity; Dipyaman Ganguly; Jit Sarkar; Sistla Ramakrishna; Balthu Narender Kumar; Kiran A Kumar; Sumit G. Gandhi; Piyush Singh Jamwal; Rekha Chouhan; Vijay Lakshmi Jamwal; Nitika Kapoor; Debashish Ghosh; Ghanshyam Thakkar; Umakanta Subudhi; Pradip Sen; Saumya Raychaudhri; Amit Tuli; Pawan Gupta; Rashmi Kumar; Deepak Sharma; Rajesh P. Ringe; Amarnarayan D; Mahesh Kulkarni; Dhanasekaran Shanmugam; Mahesh Dharne; Syed G Dastager; Rakesh Joshi; Amita P. Patil; Sachin N Mahajan; Abu Junaid Khan; Vasudev Wagh; Rakeshkumar Yadav; Ajinkya Khilari; Mayuri Bhadange; Arvindkumar H. Chaurasiya; Shabda E Kulsange; Krishna khairnar; Shilpa Paranjape; Jatin Kalita; G.Narahari Sastry; Tridip Phukan; Prasenjit Manna; Wahengbam Romi; Pankaj Bharali; Dibyajyoti Ozah; Ravi Kumar Sahu; Elapaval VSSK Babu; Rajeev K Sukumaran; Aishwarya R Nair; Anoop Puthiyamadam; Prajeesh Kooloth Valappil; Adarsh Velayudhanpillai; Kalpana Chodankar; Samir Damare; Yennapu Madhavi; Ved Varun Agrawal; Sumit Dahiya; Anurag Agrawal; Debasis Dash; Shantanu Sengupta.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21249713

RESUMO

To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India), conducted a sero-survey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS CoV2 anti-nucleocapsid (anti-NC) antibodies; 95% with surrogate neutralization activity. Three-fourth recalled no symptoms. Repeat serology tests at 3 (n=346) and 6 (n=35) months confirmed stability of antibody response and neutralization potential. Local sero-positivity was higher in densely populated cities and was inversely correlated with a 30 day change in regional test positivity rates (TPR). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of sero-positivity were high-exposure work (Odds Ratio, 95% CI, p value; 2{middle dot}23, 1{middle dot}92-2{middle dot}59, 6{middle dot}5E-26), use of public transport (1{middle dot}79, 1{middle dot}43-2{middle dot}24, 2{middle dot}8E-06), not smoking (1{middle dot}52, 1{middle dot}16-1{middle dot}99, 0{middle dot}02), non-vegetarian diet (1{middle dot}67, 1{middle dot}41-1{middle dot}99, 3{middle dot}0E-08), and B blood group (1{middle dot}36,1{middle dot}15-1{middle dot}61, 0{middle dot}001). Impact StatementWidespread asymptomatic and undetected SARS-CoV2 infection affected more than a 100 million Indians by September 2020. Declining new cases thereafter may be due to persisting humoral immunity amongst sub-communities with high exposure. FundingCouncil of Scientific and Industrial Research, India (CSIR)

3.
Sci Rep ; 8(1): 18013, 2018 12 20.
Artigo em Inglês | MEDLINE | ID: mdl-30573733

RESUMO

L-asparaginase, a therapeutic involved in cancer therapy, from Bacillus tequilensis PV9W (ansA gene) was cloned and over expressed in Escherichia coli BL21 (DE3), achieved the aim of maximizing the yield of the recombinant enzyme (6.02 ± 1.77 IU/mL) within 12 h. The native L-asparaginase of B. tequilensis PV9W was encapsulated using solid lipid particles by hot lipid emulsion method, which is reported for first time in this study. Subsequently, the lipid encapsulated L-asparaginase (LPE) was characterized by SEM, UV-Vis spectroscopy, FT-IR, SDS-PAGE and its thermo stability was also analyzed by TGA. Further characterization of LPE revealed that enzyme was highly stable for 25 days when stored at 25 °C, showed high pH (9) tolerance and longer trypsin half-life (120 min). In addition, the cytotoxic ability of LPE on HeLa cells was highly enhanced compared to the native L-asparaginase from Bacillus tequilensis PV9W. Moreover, better kinetic velocity and lower Km values of LPE aided to detect L-asparagine in cell extracts by Differential Pulse Voltammetry (DPV) method. The LPE preparation also showed least immunogenic reaction when tested on normal macrophage cell lines. This LPE preparation might thus pave way for efficient drug delivery and enhancing the stability of L-asparaginase for its therapeutic applications.


Assuntos
Asparaginase/genética , Asparaginase/uso terapêutico , Bacillus/genética , Lipídeos/química , Neoplasias/tratamento farmacológico , Animais , Asparaginase/metabolismo , Bacillus/enzimologia , Clonagem Molecular , Composição de Medicamentos , Sistemas de Liberação de Medicamentos , Ensaios de Seleção de Medicamentos Antitumorais , Enzimas Imobilizadas/genética , Enzimas Imobilizadas/metabolismo , Enzimas Imobilizadas/uso terapêutico , Regulação Enzimológica da Expressão Gênica , Células HeLa , Humanos , Gotículas Lipídicas/química , Camundongos , Neoplasias/patologia , Células RAW 264.7 , Proteínas Recombinantes/genética , Resultado do Tratamento
4.
Colloids Surf B Biointerfaces ; 171: 327-334, 2018 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-30055473

RESUMO

Increasing interests in industrialization invites acute or chronic toxicity into the environment resulting in serious ecological risks. This can be efficiently handled by bioremediation techniques. Hence in the present study, an exopolysaccharide (EPS) producing bacterium was isolated and identified as Bacillus cereus VK1 by 16S rRNA characterization. EPS was purified, estimated and further characterized by FTIR, GC-MS and TGA. Media optimization for enhanced production of EPS was done by statistical modeling which yielded a 15.49 fold increase upon supplementation of molasses (3%) and soy meal (3%). Furthermore, the cells were employed for bioremediation of Hg2+, estimated by stripping voltammetry technique. Results revealed that 20 mg (DCW) of Bacillus cereus VK1, grown in LB could adsorb up to 80.22 µg Hg2+ in 20 min, whereas bacteria grown in the RSM optimized M9 media adsorbed up to 295.53 µg Hg2+, thus B.cereus VK1 may render a strategy for the bioremediation of Hg2+ polluted eco-systems.


Assuntos
Bacillus cereus/química , Mercúrio/isolamento & purificação , Polissacarídeos/química , Mercúrio/química , Polissacarídeos/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...